In lung cancer, it has a positive correlation with pathology stage, poor prognosis, and lymph node metastasis (Chong et al., 2006), it promotes ovarian cancer progression and chemoresistance to cisplatin and paclitaxel via activating NF‐KB, and it promotes the expression of TWIST1, MCL1(Wu, Huang, Chang, & Chou, 2017). Here, NFKB1 is linked to lung carcinoma.